$2495 | Single User
$4995 | Global License

NPS+ Myeloma (US) 2016
[Report Updated: 01-12-2016]

Published by FirstWord Pharma: 01 Dec 2016 | 65337 | In Stock
Related Topics: Multiple Myeloma , Myeloma , Novartis

Introduction

Overall satisfaction is high, but three brands are way ahead. Can your brand catch up?

Our survey of 100 medical oncologists and haematologists shows that while US doctors are happy with available myeloma therapies, some brands are doing a whole lot better than others. Can mid-ranked brands catch up to the three market leaders? Can the two lagging brands lift their scores out of negative territory?

Find out how your brand is doing, and how to improve, in FirstView NPS+ Multiple Myeloma (US).

The report builds on the respected net promoter score (NPS) to compare loyalty for 9 Myeloma drugs, highlighting ways you can improve brand health—and boost market share—with easy-to-use KPIs.

Plus, candid feedback from respondents reveals which brand one doctor said would “probably become standard of care” and which brand one referred to as, “a mediocre tool that needs a crutch to work.”

Top Takeaways

Three clear winners: The three leading brands have significantly higher scores than the rest of the pack. The top two brands also lead the EU5 market.

Nearly all brands have positive NPS: Only two of the nine surveyed brands have negative scores, and both are deep in negative territory.

Two brands poised for massive share gains: The two lowest ranking brands stand to quintuple and quadruple their market share respectively if they can turn their Detractors into Promoters.

High satisfaction, low loyalty market: Most of the doctors we surveyed are satisfied with available treatments, but are willing to switch freely. Doctors who recommend one brand tend to also recommend up to 6 or more other brands.

“Passive” potential for middle-ranking brands: Several brands in the middle of the pack have high numbers of “Passives” who are more closely aligned with Promoters than Detractors. Winning them over could be the key to competing with leading brands.

Cost is an important concern: Although messages related to cost don’t necessarily resonate with many doctors, it is a top-3 driver of recommendations for five of the nine surveyed brands.

Insight into 9 Major Myeloma Brands

Darzalex (daratumumab; Johnson & Johnson)

Empliciti (elotuzumab; BMS/AbbVie)

Farydak (panobinostat; Novartis)

Kyprolis (carfilzomib; Amgen)

Ninlaro (ixazomib; Takeda)

Pomalyst (pomalidomide; Celgene)

Revlimid (lenalidomide; Celgene)

Thalomid (thalidomide; Celgene)

Velcade (bortezomib; Takeda)

A Report Based on Expert Knowledge

We surveyed 100 US medical oncologists and haematologist, chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between October 3rd and 17th, 2016.

Explore Important Brand Loyalty Issues

NPS+ Multiple Myeloma (EU5) explores key issues affecting brand loyalty for drug manufacturers. You’ll learn:

How satisfied the Myeloma market is.

How loyal doctors are to your brand.

How many other brands your Promoters recommend.

Which other brands your Promoters and Detractors recommend.

How much market share your brand has among Promoters and Detractors.

How much market share you stand to gain by converting Detractors into Promoters.

Which messages Promoters, Passives and Detractors associate with your brand.

Your brand DNA: what doctors really think of your brand—in their own words.

What is Net Promoter® Score?

NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?

NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:

Detractors are those who answer 0 – 6.

Passives are those who answer 7 – 8.

Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

MONEY BACK GUARANTEE!

At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.

About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.

FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.

FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Table of Contents
for NPS+ Myeloma (US) 2016 [Report Updated: 01-12-2016]

  • 1.Chart 1: Net Promoter Score?

    2.Chart 2: How loyal are doctors to my brand?

    3.Chart 3: How satisfied is the market?

    4.Chart 4: How many other brands are promoted by my Promoters?

    5.Chart 5: Which other brand is most promoted by my Promoters?

    6.Chart 6: Which other brands are promoted by my Detractors?

    7.Chart 7: What is my brand's market share among Promoters and Detractors?

    8.Chart 8: What brand messages are associated with Promoters, Passives and Detractors (by

    brand)?

    9.Chart 9: What does my brand represent to Promoters and Detractors (by brand)?

    10.Appendix

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

65337 |

Report Format

PDF

FirstWord Pharma Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Effective Pharma KAM Teams: Challenges and solutions from the front line (2016)
IntroductionThe essentials for getting your KAM strategy right There are many factors currently affe...
01 Feb 2016 by FirstWord Pharma USD $695 More Info
Ulcerative Colitis: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events happening in Ulcerative Colitis. Topics cover...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Prostate Cancer: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Innovations in Drug Pricing and Reimbursement (2016)
IntroductionIs the drug pricing bubble about to burst?Drug costs are becoming unaffordable and draco...
01 Feb 2016 by FirstWord Pharma USD $2,195 More Info
Biosimilars in Oncology: Update Bulletin [Feb 2016]
Introduction new KOL insights on the latest events that have the potential to shape the oncology bio...
01 Feb 2016 by FirstWord Pharma USD $995 More Info
Biosimilars: European Payer Perspectives (2016)
IntroductionWhat’s driving the uptake of biosimilars in Europe and what still needs to be done?The E...
01 Jan 2016 by FirstWord Pharma USD $2,195 More Info
Pharma Marketing 2020 (2016)
IntroductionHow can pharma marketing effectively meet future communication challenges in a rapidly c...
01 Jan 2016 by FirstWord Pharma USD $695 More Info
Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events that have the potential to shape the targeted...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
Malignant Melanoma: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’...
01 Jan 2016 by FirstWord Pharma USD $995 More Info
Type 2 Diabetes Mellitus: Update Bulletin [Jan 2016]
IntroductionGain new KOL insights on the latest events happening in type 2 diabetes mellitus (T2DM):...
01 Jan 2016 by FirstWord Pharma USD $995 More Info

This report is published by FirstWord Pharma

Download Free Report Summary PDF

NPS+ Myeloma (US) 2016 [Report Updated: 01-12-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...